Journal Article

Is It Possible to Blind a Trial for Community-Acquired Pneumonia?

Helen W. Boucher

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 47, issue Supplement_3, pages S210-S215
Published in print December 2008 | ISSN: 1058-4838
Published online December 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/591428
Is It Possible to Blind a Trial for Community-Acquired Pneumonia?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Blinding a randomized, controlled clinical trial provides benefits on several levels but often is not perfectly executed or well described. Most recent registration trials of therapy for community-acquired pneumonia were designed and conducted as blinded trials, although the descriptions of blinding were frequently incomplete. Issues related to definitions, conduct, testing success, and reporting of blinding are addressed in this article. The benefits of blinding clinical trial participants, study drug assignment, microbiological data, and outcome assessments of both efficacy and safety are presented. Particular attention is paid to challenges inherent in the blinding of trials of therapy for pneumonia, especially in trials involving seriously ill patients who require intravenous therapy.

Journal Article.  4319 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.